Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) fell 6.2% during trading on Friday . The company traded as low as $1.34 and last traded at $1.37. 2,391,282 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 3,165,420 shares. The stock had previously closed at $1.46.

A number of brokerages have recently commented on IDXG. Maxim Group began coverage on shares of Interpace Diagnostics Group in a research report on Tuesday, August 15th. They issued a “buy” rating and a $5.00 target price for the company. ValuEngine upgraded shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th.

The firm’s market capitalization is $30.36 million. The company’s 50 day moving average price is $1.52 and its 200 day moving average price is $1.56.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its earnings results on Thursday, August 10th. The business services provider reported ($0.65) earnings per share for the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%. The firm had revenue of $3.86 million during the quarter.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC bought a new stake in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned about 2.39% of Interpace Diagnostics Group at the end of the most recent quarter. 7.41% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.